"Unser Haus steht für Fortschritt und Menschlichkeit, eine Haltung, die für alle (er-)lebbar sein soll - Patienten, Angehörige und Mitarbeitende. Deswegen sind wir stolz darauf, dass unser Krankenhaus bereits mehrfach, zuletzt 2019, zertifiziert und ausgezeichnet wurde. Das Johanna Etienne Krankenhaus ist ein Krankenhaus der Grund- und Regelversorgung mit einigen herausragenden Spezialgebieten, die über die Region hinaus bekannt und in ihrer Expertise führend sind. Das Haus ist seinen katholischen Wurzeln eng verbunden und pflegt diese auch im Umgang mit den Patienten. Über 1000 Mitarbeiterinnen und Mitarbeiter sorgen sich jährlich um insgesamt 80 000 stationär und ambulante Patienten. Das Haus verfügt über 415 Betten."

During the past decade, Johanna Etienne Krankenhaus conducted 8 clinical trials. In the 10-year time frame, 8 clinical trials started and 2 clinical trials were completed, i.e. on average, 25% percent of trials that started reached the finish line to date. In the past 5 years, 8 clinical trials started and 2 clinical trials were completed. i.e. 25% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Johanna Etienne Krankenhaus" #1 sponsor was "Abivax S.A." with 2 trials, followed by "Arena Pharmaceuticals" with 2 trials sponsored, "Genzyme, a Sanofi Company" with 2 trials sponsored, "Pfizer" with 2 trials sponsored and "Actamax Surgical Materials LLC" with 2 trials sponsored. Other sponsors include -2 different institutions and companies that sponsored additional 8 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Johanna Etienne Krankenhaus" #1 collaborator was "Arena is a wholly owned subsidiary of Pfizer" with 2 trials as a collaborator, "Amgen" with 1 trials as a collaborator and "Ipsen" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "Johanna Etienne Krankenhaus" are "Ulcerative Colitis" (6 trials), "Breast Neoplasms" (1 trials), "Hepatocellular Carcinoma Non-resectable" (1 trials), "Metastatic Hepatocellular Carcinoma" (1 trials) and "Musculoskeletal Diseases" (1 trials). Many other conditions were trialed in "Johanna Etienne Krankenhaus" in a lesser frequency.

Most popular intervention types in "Johanna Etienne Krankenhaus" are "Drug" (7 trials), "Device" (4 trials), "Other" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Etrasimod" (4 trials), "Placebo" (4 trials), "ABX464" (1 trials), "ABX464 100mg" (1 trials) and "ABX464 25mg" (1 trials). Other intervention names were less common.

The vast majority of trials in "Johanna Etienne Krankenhaus" are 10 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "Johanna Etienne Krankenhaus". undefined are not yet recruiting, 3 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 8 completed trials in Johanna Etienne Krankenhaus, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Johanna Etienne Krankenhaus, 2 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 5 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".